Detection of leukemia-derived microparticles in the monitoring of chronic myeloid leukemia.
- VernacularTitle:白血病细胞来源微粒BCR-ABL mRNA检测在监测慢性髓性白血病治疗反应中的意义
- Author:
Xiaojian ZHU
1
;
Qing LI
1
;
Chen ZENG
1
;
Zhaodong ZHONG
1
;
Yong YOU
1
;
Ping ZOU
1
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Cell-Derived Microparticles; Child; Female; Fusion Proteins, bcr-abl; genetics; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; genetics; therapy; Male; Middle Aged; RNA, Messenger; genetics; Real-Time Polymerase Chain Reaction; Young Adult
- From: Chinese Journal of Hematology 2014;35(2):138-141
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo exam the role of leukemia cells-derived microparticles in the post-complete molecular response stratification.
METHODSBlood samples from 29 patients diagnosed with chronic myeloid leukemia (CML) were collected. Microparticles (MP) were extracted from the peripheral blood. Real-time PCR was performed to measure the level of BCR-ABL mRNA.
RESULTSBCR-ABL mRNA could be stably detected both in MP and peripheral blood cells; BCR-ABL in MP showed significant difference within complete molecular response, major molecular response and complete cytogenetic response (9.1±2.8, 25.2±6.9 and 62.8±6.3 respectively, P<0.05). BCR-ABL was detected in MP even when it was negative in peripheral blood cells (3.7-15.3). For patients with complete molecular response, BCR-ABL in MP but not cells were significantly different between imatinib and stem cell transplant recipients (3.3±2.1 vs 9.1±2.8, P<0.05).
CONCLUSIONThis study indicated that MP may serves as a new target for monitoring of CML. Quantification of BCR-ABL in MP may offer a novel strategy for stratification of molecular response.
